MissionIR's  Instablog

Send Message
We know our reputation is based on the integrity of our clients and go to great lengths to ensure the companies represented adhere to sound business practices. It is our unwavering commitment to connect the investment community with companies that have great potential and a strong dedication to... More
My company:
My blog:
MissionIR Blog
  • CytRx Corp. (CYTR) Continues Positive Trajectory, Says Wall St. Cheat Sheet Contributor 0 comments
    Jan 13, 2014 5:31 PM | about stocks: CYTR

    Biotech small-cap CytRx is getting a lot of attention lately - stemming from positive top-line results of its phase 2b study of lead candidate aldoxorubicin, as well as from a more than three-month bull-run of the company's stock. Wall St. Cheat Sheet contributing writer Matt Levy is the latest of several market writers to highlight the CytRx's achievements and market potential.

    To read the full article visit: wallstcheatsheet.com/stocks/good-news-co.../

    Levy starts his recent article on CytRx by noting the stock's triple-digit gains following the CytRx's phase 2b trial results in which aldoxorubicin demonstrated superiority over current standard of care chemotherapeutic agent, doxorubicin.

    "The news was extremely positive and investors have become big believers in both the company and the science. The upward momentum continued on January 8 when the company reported additional analyses from the Phase 2b trial in STS. When trying to analyze data, one of the more important components to look at is the hazard ratio. In the case of aldoxorubicin, the hazard ratio allows doctors to determine the likelihood that tumor progression will be reached during a specified period. Hazard ratios less than 1 indicate that there is a substantial benefit of aldoxorubicin over doxorubicin. The additional analyses reported on January 8 provided hazard ratios for both the investigator-read scans and the central lab scans."

    Levy further details the design, outcome, and importance of the clinical trial before highlighting two positive analyst actions on CytRx's stock following the trial results. He also outlines aldoxorubicin's potential for the treatment of glioblastoma, the most common and fatal form of brain cancer.

    "It appears that all signs are pointing to a company that is on the verge of giving hope to cancer patients around the world. Patients often struggle with the decision to go through the ordeal of cancer treatment, such as chemotherapy, because of the painful side effects that can occur. CytRx may one day replace doxorubicin and offer patients an alternative treatment that is not only more effective but less harmful," Levy concludes.

    For more information, visit CytRx.com

    MissionIR provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.missionir.com

    Stocks: CYTR
Back To MissionIR's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers


More »
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.